MedTrace Logo

Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients

NCT03721133 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-05-22

No results posted yet for this study

Summary

From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients. In addition, circulating tumor cell usual aggregate to form circulating tumor micro-emboli and caused distant metastases. Therefore, circulating tumor cell could play a role in detect disease relapse and appropriate treatment could be given more earlier and further prolong patients' survival. However, the detail clinical significance of circulating tumor still remains unknown. The aim of this study was evaluate the clinical significance, including present timing, numbers, and correlation to disease relapse, of circulating tumor cell in lung cancer patients. The investigators want to clarify the clinical significance between circulating tumor cell and clinical presentation of lung cancer in order to establish new prediction model and improve lung cancer patients' survival.

Conditions

  • Lung Cancer Recurrent

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chia-Hsun Hsieh, MD · Chang Gung Memorial Hospital

  • Yi-Cheng Wu, MD · Chang Gung Memorial Hospital

  • Cheng-Ta Yang, MD · Chang Gung Memorial Hospital

  • JUI-YING Fu, MD · Chang Gung Memorial Hospital

  • ChingFeng Wu, MD · Chang Gung Memorial Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-04
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03721133 on ClinicalTrials.gov